Sign in

    Matthew Barcus

    Senior Research Associate at Jefferies

    Matthew Barcus is a Senior Research Associate at Jefferies, specializing in equity research with a focus on biotechnology and related healthcare sectors. He has covered emerging biotech companies and contributed to in-depth analysis in support of lead analysts recognized on industry platforms, though individual performance metrics and rankings are not publicly available. Barcus began his research career after earning advanced academic credentials, previously serving as a Director at Chardan Capital Markets before joining Jefferies in New York City. He holds a FINRA Series 7 and Series 63 registration, reflecting his professional licensure in securities research and analysis.

    Matthew Barcus's questions to RELMADA THERAPEUTICS (RLMD) leadership

    Matthew Barcus's questions to RELMADA THERAPEUTICS (RLMD) leadership • Q1 2025

    Question

    Matthew Barcus from Jefferies inquired about the timeline for the complete response rate data for the full NDV-01 patient cohort, future data updates, and the company's ideal design for a potential Phase III trial, including endpoints and patient populations.

    Answer

    Executive Sergio Traversa stated that 6-month data for the initial 20 patients in the NDV-01 study will be available around June/July, with 9 and 12-month data to follow. Dr. Yair Lotan, a clinical expert, highlighted that the safety profile is the most reassuring aspect of the data so far. For the Phase III design, Dr. Lotan outlined two potential efficient pathways: a single-arm chemoablation trial, pending FDA's view on a similar competitor product, or a randomized trial against placebo in intermediate-risk patients, which he noted would likely enroll quickly.

    Ask Fintool Equity Research AI

    Matthew Barcus's questions to Vistagen Therapeutics (VTGN) leadership

    Matthew Barcus's questions to Vistagen Therapeutics (VTGN) leadership • Q3 2025

    Question

    Matthew Barcus of Jefferies inquired about the timeline for PALISADE-3 and 4 data, confidence in study execution, and the competitive landscape for social anxiety disorder (SAD) treatments.

    Answer

    CEO Shawn Singh confirmed the 2025 data timeline for the PALISADE-3 and 4 trials remains on track. COO Joshua Prince and CEO Shawn Singh both expressed high confidence in study execution, citing enhanced surveillance, rigorous protocol adherence, and expanded internal team involvement as key improvements. Regarding competition, Singh highlighted fasedienol's unique nose-to-brain mechanism, which avoids systemic absorption and differentiates it from other potential treatments in the large SAD market.

    Ask Fintool Equity Research AI

    Matthew Barcus's questions to Vanda Pharmaceuticals (VNDA) leadership

    Matthew Barcus's questions to Vanda Pharmaceuticals (VNDA) leadership • Q3 2024

    Question

    Matthew Barcus, on for Andrew Tsai, asked how Vanda is balancing the Fanapt and PONVORY launches, if the Q3 PONVORY inventory destocking was resolved, the size of the PONVORY sales force, and the expected timing for marketing efforts to impact revenue. He also inquired about the company's strategy for its early-stage pipeline, including potential partnerships.

    Answer

    CEO Mihael Polymeropoulos clarified that Fanapt and PONVORY have separate, specialized sales forces. Executive Kevin Moran confirmed the PONVORY inventory destocking was a temporary issue related to the distribution transition from Janssen and was resolved in October. He stated the PONVORY sales force numbers around 30 representatives and that the impact of marketing efforts should begin to be reflected in revenue later this year and into 2025. Dr. Polymeropoulos described the pipeline strategy as maintaining a balanced portfolio and that partnering decisions would be evaluated as assets mature.

    Ask Fintool Equity Research AI